146944-34-5

Basic information

• Product Name: BUTTPARK 121\16-92
• Synonyms: BUTTPARK 121\16-92;TERT-BUTYL (4-BENZYLMORPHOLIN-2-YL)METHYLCARBAMATE;CarbaMic acid, N-[[4-(phenylMethyl)-2-Morpholinyl]Methyl]-, 1,1-diMethylethyl ester
• CAS NO: 146944-34-5
• Molecular Formula: C₁₇H₂₆N₂O₃
• Molecular Weight: 306.4
• Mol File: 146944-34-5.mol

Chemical Properties

• Boiling Point: 423.1±25.0 °C(Predicted)
• Appearance: /
• Density: 1.083±0.06 g/cm3(Predicted)
• PKA: 12.22±0.46(Predicted)
• CAS DataBase Reference: BUTTPARK 121\16-92(CAS DataBase Reference)
• NIST Chemistry Reference: BUTTPARK 121\16-92(146944-34-5)
• EPA Substance Registry System: BUTTPARK 121\16-92(146944-34-5)

Safety Data

• Hazardous Substances Data: 146944-34-5(Hazardous Substances Data)

Upstream product

• 112913-97-0 2-(azidomethyl)-4-benzylmorpholine 
• 40987-25-5 N-benzyl-2-chloromethylmorpholine 
• 104-63-2 N-Benzylethanolamine 
• 100-52-7 benzaldehyde 
• 51779-32-9 iminodicarboxylic acid di-tert-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 110859-47-7 (4-benzylmorpholin-2-yl)methanamine 

Downstream Products

• 875551-47-6 1,1-dimethylethyl {[(2R)-4-(phenylmethyl)-2-morpholinyl]methyl}carbamate 
• 186293-56-1 1,1-dimethylethyl {[(2S)-4-(phenylmethyl)-2-morpholinyl]methyl}carbamate 
• 173341-02-1 N-(morpholin-2-ylmethyl)carbamic acid tert-butyl ester 

Relevant articles and documents

INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS

The present invention relates to novel indazole compounds of the Formula (I), wherein, R1 is alkyl or cycloalkyl; (Formula II) including their stereoisomers and their pharmaceutically acceptable salts. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to 5-Hydroxytryptamine 4 (5-HT4) receptor agonists

AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

Disclosed is a compound having a strong affinity to serotonin-4 receptors, which is useful as an enterokinesis-promoting agent or a digestive tract function-improving agent. Specifically, disclosed is a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof. Also specifically disclosed is a pharmaceutical composition containing a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof. [In Formula (1), Ar represents a group represented by Formula (Ar-1) or Formula (Ar-2).]

HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIBACTERIALS

Tricyclic nitrogen containing compounds of formula (I) and their use as antibacterials .

ANTIBACTERIAL AGENTS

Naphthalene, quinoline, quinoxaline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.

NOVEL COMPOUNDS HAVING AN ANTI-BACTERIAL ACTIVITY

The present invention describes novel anti-bacterial compounds of formula (I). These compounds are, amongst others, of interest as inhibitors of DNA gyrase.

NOVEL COMPOUNDS WITH ANTIBACTERIAL ACTIVITY

The invention relates to novel antibacterial compounds of formula (I).

Sulfonamidocarboxamides

Sulfonamidocarboxamides of the formula STR1 wherein A, M, Q, X and Y have the significance given in the description, as well as hydrates, solvates and salts thereof, which inhibit thrombin-induced blood platelet aggregation and clotting of fibrinogen in plasma, as described. The compounds of formula I can be prepared by amidination of a cyclic amino group standing for grouping X or by C(O)N(Q) amide formation.